Skip to main content

Cholangiocarcinoma Specialty Channel

Cholangiocarcinoma
Specialty Channel
Conference Coverage
05/28/2024
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial...
05/28/2024
Oncology
News
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
01/20/2024
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study...
01/20/2024
Oncology
Conference Coverage
01/19/2024
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a...
01/19/2024
Oncology
Conference Coverage
01/19/2024
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with...
01/19/2024
Oncology
News
11/02/2023
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA...
11/02/2023
Oncology
News
07/20/2023
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab...
07/20/2023
Oncology
Conference Coverage
06/29/2023
According to phase 3 data presented at the 2023 ESMO World Congress on Gastrointestinal Cancers, NUC-1031 plus cisplatin did not improve the overall survival among patients with advanced biliary tract cancers, vs gemcitabine-cisplatin.
According to phase 3 data presented at the 2023 ESMO World Congress on Gastrointestinal Cancers, NUC-1031 plus cisplatin did not improve the overall survival among patients with advanced biliary tract cancers, vs gemcitabine-cisplatin.
According to phase 3 data...
06/29/2023
Oncology
Quiz
06/15/2023
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with...
06/15/2023
Oncology
Quiz
06/15/2023
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose...
06/15/2023
Oncology
Conference Coverage
06/02/2023
The FGFR-selective tyrosine kinase inhibitor (TKI) HMPL-453 was found to be effective and safe for patients with advanced intrahepatic cholangiocarcinoma.
The FGFR-selective tyrosine kinase inhibitor (TKI) HMPL-453 was found to be effective and safe for patients with advanced intrahepatic cholangiocarcinoma.
The FGFR-selective tyrosine...
06/02/2023
Oncology

News

Conference Coverage
05/28/2024
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial...
05/28/2024
Oncology
News
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
01/20/2024
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study...
01/20/2024
Oncology
Conference Coverage
01/19/2024
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a...
01/19/2024
Oncology
Conference Coverage
01/19/2024
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with...
01/19/2024
Oncology
News
11/02/2023
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA...
11/02/2023
Oncology
News
07/20/2023
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab...
07/20/2023
Oncology
Conference Coverage
06/29/2023
According to phase 3 data presented at the 2023 ESMO World Congress on Gastrointestinal Cancers, NUC-1031 plus cisplatin did not improve the overall survival among patients with advanced biliary tract cancers, vs gemcitabine-cisplatin.
According to phase 3 data presented at the 2023 ESMO World Congress on Gastrointestinal Cancers, NUC-1031 plus cisplatin did not improve the overall survival among patients with advanced biliary tract cancers, vs gemcitabine-cisplatin.
According to phase 3 data...
06/29/2023
Oncology
Conference Coverage
06/02/2023
The FGFR-selective tyrosine kinase inhibitor (TKI) HMPL-453 was found to be effective and safe for patients with advanced intrahepatic cholangiocarcinoma.
The FGFR-selective tyrosine kinase inhibitor (TKI) HMPL-453 was found to be effective and safe for patients with advanced intrahepatic cholangiocarcinoma.
The FGFR-selective tyrosine...
06/02/2023
Oncology
Conference Coverage
01/20/2023
According to a phase 2 trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium, the LAT1-inhibitor nanvuranlat significantly improved progression-free survival for patients with advanced refractory biliary tract cancers, compared...
According to a phase 2 trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium, the LAT1-inhibitor nanvuranlat significantly improved progression-free survival for patients with advanced refractory biliary tract cancers, compared...
According to a phase 2 trial...
01/20/2023
Oncology

Quiz
06/15/2023
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with...
06/15/2023
Oncology
Quiz
06/15/2023
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose...
06/15/2023
Oncology
Quiz
05/09/2023
In what percentage of patients with cholangiocarcinoma does an IDH mutation occur?
In what percentage of patients with cholangiocarcinoma does an IDH mutation occur?
In what percentage of patients...
05/09/2023
Oncology
Quiz
04/11/2023
Which type of biliary tract cancer is more likely to be IDH-mutant?
Which type of biliary tract cancer is more likely to be IDH-mutant?
Which type of biliary tract...
04/11/2023
Oncology
Quiz
12/01/2022
How did the outcomes of patients with unresectable perihilar cholangiocarcinoma who were treated with neoadjuvant chemoradiotherapy and liver transplant compare to the outcomes of patients with perihilar cholangiocarcinoma who underwent...
How did the outcomes of patients with unresectable perihilar cholangiocarcinoma who were treated with neoadjuvant chemoradiotherapy and liver transplant compare to the outcomes of patients with perihilar cholangiocarcinoma who underwent...
How did the outcomes of patients...
12/01/2022
Oncology
Quiz
11/30/2022
What was the approximate objective response rate seen for patients with HER2-positive biliary tract cancer treated with the trastuzumab-pkrb biosimilar plus modified FOLFOX chemotherapy in the second- or third-line setting?
What was the approximate objective response rate seen for patients with HER2-positive biliary tract cancer treated with the trastuzumab-pkrb biosimilar plus modified FOLFOX chemotherapy in the second- or third-line setting?
What was the approximate...
11/30/2022
Oncology
Quiz
11/02/2022
In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with interhepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?
In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with interhepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?
In the phase 2 FIDES-01 study,...
11/02/2022
Oncology
Test Your Knowledge
02/24/2022
Which test can be used to compare overall survival (OS) and disease-free survival (DFS) in intrahepatic cholangiocarcinoma (ICC)?
Which test can be used to compare overall survival (OS) and disease-free survival (DFS) in intrahepatic cholangiocarcinoma (ICC)?
Which test can be used to...
02/24/2022
Oncology
Quiz
02/14/2022
The FDA’s approval of pemigatinib was based on a clinical trial of 107 pretreated patients with locally advanced or metastatic cholangiocarcinoma and _____ fusion or rearrangement.
The FDA’s approval of pemigatinib was based on a clinical trial of 107 pretreated patients with locally advanced or metastatic cholangiocarcinoma and _____ fusion or rearrangement.
The FDA’s approval of...
02/14/2022
Oncology
Test Your Knowledge
08/28/2020
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did...
08/28/2020
Oncology